MilliporeSigma claims ‘first-of-its-kind’ resin improves efficiency across the board

By Ben Hargreaves contact

- Last updated on GMT

(Image: Pixabay/Prawny)
(Image: Pixabay/Prawny)

Related tags: MilliporeSigma, Resin

MilliporeSigma used Biotech Week Boston to discuss the release of its Eshmuno CP-FT resin and how it can improve downstream efficiency.

MilliporeSigma arrived at Biotech Week Boston ready to outline why its newly developed Eshmuno CP-FT resin marks an improvement over competitor products.

With this in mind, the company released statistics suggesting that the ‘flow-through’ frontal chromatography technology can enable loading capacities 10 times higher than traditional methods.

We spoke to Mike Felo, director of downstream process integration at MilliporeSigma, at the event to discover how the technology came about and what he believes it will bring to downstream processing. Felo said that the new technology is part of an industry move towards ‘process intensification’.

He explained, “Process intensification is a buzzword that means taking a look at the manufacturing process and trying to figure out how to make it smaller, modular, with lower labour requirements and higher automation. This feeds into the overall aim of running continuously, where we can produce the monoclonal antibody and then purify it in one, continuous process.”

In terms of how the new resin marks a departure from standard technology, he said: “Traditionally, what we’ve tried to do at the final stage of polishing is to bind the antibody to a resin column and then wash off the impurities. What we’ve tried to do with Eshmuno CP-FT resin is to bind the impurities individually; so, if you’re only binding impurities at a 3% level then we only have to design a resin that captures this fraction rather than 100% and then remove the impurities along the way.”

Felo noted this is how the technology is able to achieve the improved loading capacities, which he told us had also been observed practically through the creation of partner consortiums with Sandoz and Lek to test the technology.

In addition, he told us that one of the significant advantages is the improved efficiency of the process: “We’re seeing a 10% overall improvement in efficiency – in costs for the overall process, it also reduces labour, and buffer use by up to 50%.”

Related news

Show more

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...


Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Related suppliers

Follow us


View more